Cargando…
Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
Duchenne muscular dystrophy (DMD) is the most common degenerative neuromuscular disease. The incidence of DMD in live births is 1/3,600-1/6,000. Although glucocorticoid-dependent medication is the mainstay treatment option for DMD, a standard treatment regimen has yet to be determined. The present r...
Autores principales: | Zhang, Tianyuan, Kong, Xiangdong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967797/ https://www.ncbi.nlm.nih.gov/pubmed/33777191 http://dx.doi.org/10.3892/etm.2021.9875 |
Ejemplares similares
-
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy
por: Wilton-Clark, Harry, et al.
Publicado: (2023) -
Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017) -
Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy
por: Kao, Kung-Ting, et al.
Publicado: (2019) -
CRISPR technologies for the treatment of Duchenne muscular dystrophy
por: Choi, Eunyoung, et al.
Publicado: (2021) -
Advances in genetic therapeutic strategies for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2015)